SAN FRANCISCO--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq:GILD) today announced results of two long-term studies evaluating ambrisentan, an investigational endothelin receptor antagonist (ERA) for the treatment of patients with pulmonary arterial hypertension (PAH). These long-term data are from patients who originally participated in the two pivotal Phase III ARIES studies and AMB-222, a Phase II study of patients who had previously discontinued other ERAs because of liver function abnormalities. These studies were selected for oral presentation at ATS 2007, the International Conference of the American Thoracic Society, taking place in San Francisco, California, May 18-23.
